Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Condition

Status epilepticus

12

Unknown

2,596

Pain

619

Cancer

609

Hypertension

575

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Approved Rx

11

US Previously Marketed

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

GABA-A receptor; anion channel

6

Sodium channel protein type I alpha subunit

5

Sodium channel protein type II alpha subunit

5

Sodium channel protein type III alpha subunit

5

Sodium channel protein type VIII alpha subunit

5

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

11

Phase III

1

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1912

6

1938

5

2019

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

12

Preventing

6

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

12

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Farbenfab Vorm Bayer F

6

Parke Davis

5

Sage Therapeutics

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

12

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

FDA UNII

12

PUBCHEM

12

CAS

11

SMS_ID

11

EVMPD

10

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

NERVOUS SYSTEM

4

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIEPILEPTICS

4

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTIEPILEPTICS

4

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Barbiturates and derivatives

2

Hydantoin derivatives

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

9

Principal Form

3

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 10 of 12 results

First page disabled
Previous page disabled
1
Next page
Next page

PHENYTOIN

6158TKW0C5

Export Data
Search for Structure

Status:

US Approved Rx (1996)

First approved in 1938

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Sodium channel protein type III alpha subunit

Sodium channel protein type I alpha subunit

Sodium channel protein type VIII alpha subunit

Sodium channel protein type II alpha subunit

Conditions:

Status epilepticus

Phenytoin is an anti-epileptic drug. Phenytoin has been used with much clinical success against all types of epileptiform seizures, except petit mal epilepsy. Phenytoin is a available for oral administration (tablets, capsules, suspension). CEREBYX®...

(fosphenytoin sodium injection) is a prodrug intended for parenteral administration; its active metabolite is phenytoin. CEREBYX should be used only when oral phenytoin administration is not possible. Although several potential targets for phenytoin action have been identified within the CNS (Na-K-ATPase, the GABAA receptor complex, ionotropic glutamate receptors, calcium channels and sigma binding sites) to date, though, the best evidence hinges on the inhibition of voltage-sensitive Na channels in the plasma membrane of neurons undergoing seizure activity.

PHENOBARBITAL SODIUM

SW9M9BB5K3

Export Data
Search for Structure

Status:

US Approved Rx (2022)

First marketed in 1912

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

GABA-A receptor; anion channel

Conditions:

Tonic-clonic seizures

Febrile seizures

Hyperbilirubinemia

Status epilepticus

Phenobarbital is a barbiturate derivative used to treat insomnia and anxiety, seizures, hyperbilirubinemia in neonates and cholestasis. Phenobarbital promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride cur...

rents through receptor channels.

BREXANOLONE

S39XZ5QV8Y

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 2019

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

GABA-A receptor; agonist GABA site

Conditions:

Postnatal depression

Status epilepticus

Essential tremor

Allopregnanolone is a neurosteroid metabolite of progesterone. It is an allosteric modulator of inhibitory γ-aminobutyric acid (GABA-A) receptors on neural stem cells and other cell types in the brain. Allopregnanolone has effects similar to those of...

other positive allosteric modulators of the GABA action at GABAA receptor such as the benzodiazepines, including anxiolytic, sedative, and anticonvulsant activity. A solution of allopregnanolone, SAGE-547 is an intravenous allosteric modulator of both synaptic and extrasynaptic γ-aminobutyric acid type A (GABAA)receptors. It's believed that allopregnanolone is effective as an anticonvulsant when prolonged seizure activity has become resistant to benzodiazepine treatment. Under the names brexanolone and SAGE-547, allopregnanolone is under development by SAGE Therapeutics as an intravenously administered drug for the treatment of super-refractory status epilepticus, postpartum depression, and essential tremor. Allopregnanolone is in phase III trials for the treatment of super-refractory status epilepticus (SRSE) and postpartum depression.

FOSPHENYTOIN

B4SF212641

Export Data
Search for Structure

Status:

US Approved Rx (1996)

First approved in 1938

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Sodium channel protein type III alpha subunit

Sodium channel protein type I alpha subunit

Sodium channel protein type VIII alpha subunit

Sodium channel protein type II alpha subunit

Conditions:

Status epilepticus

Phenytoin is an anti-epileptic drug. Phenytoin has been used with much clinical success against all types of epileptiform seizures, except petit mal epilepsy. Phenytoin is a available for oral administration (tablets, capsules, suspension). CEREBYX®...

(fosphenytoin sodium injection) is a prodrug intended for parenteral administration; its active metabolite is phenytoin. CEREBYX should be used only when oral phenytoin administration is not possible. Although several potential targets for phenytoin action have been identified within the CNS (Na-K-ATPase, the GABAA receptor complex, ionotropic glutamate receptors, calcium channels and sigma binding sites) to date, though, the best evidence hinges on the inhibition of voltage-sensitive Na channels in the plasma membrane of neurons undergoing seizure activity.

FOSPHENYTOIN SODIUM HEPTAHYDRATE

9X1NTA9SRP

Export Data
Search for Structure

Status:

US Approved Rx (1996)

First approved in 1938

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Sodium channel protein type III alpha subunit

Sodium channel protein type I alpha subunit

Sodium channel protein type VIII alpha subunit

Sodium channel protein type II alpha subunit

Conditions:

Status epilepticus

Phenytoin is an anti-epileptic drug. Phenytoin has been used with much clinical success against all types of epileptiform seizures, except petit mal epilepsy. Phenytoin is a available for oral administration (tablets, capsules, suspension). CEREBYX®...

(fosphenytoin sodium injection) is a prodrug intended for parenteral administration; its active metabolite is phenytoin. CEREBYX should be used only when oral phenytoin administration is not possible. Although several potential targets for phenytoin action have been identified within the CNS (Na-K-ATPase, the GABAA receptor complex, ionotropic glutamate receptors, calcium channels and sigma binding sites) to date, though, the best evidence hinges on the inhibition of voltage-sensitive Na channels in the plasma membrane of neurons undergoing seizure activity.

PHENYTOIN SODIUM

4182431BJH

Export Data
Search for Structure

Status:

US Approved Rx (1996)

First approved in 1938

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Sodium channel protein type III alpha subunit

Sodium channel protein type I alpha subunit

Sodium channel protein type VIII alpha subunit

Sodium channel protein type II alpha subunit

Conditions:

Status epilepticus

Phenytoin is an anti-epileptic drug. Phenytoin has been used with much clinical success against all types of epileptiform seizures, except petit mal epilepsy. Phenytoin is a available for oral administration (tablets, capsules, suspension). CEREBYX®...

(fosphenytoin sodium injection) is a prodrug intended for parenteral administration; its active metabolite is phenytoin. CEREBYX should be used only when oral phenytoin administration is not possible. Although several potential targets for phenytoin action have been identified within the CNS (Na-K-ATPase, the GABAA receptor complex, ionotropic glutamate receptors, calcium channels and sigma binding sites) to date, though, the best evidence hinges on the inhibition of voltage-sensitive Na channels in the plasma membrane of neurons undergoing seizure activity.

FOSPHENYTOIN SODIUM

7VLR55452Z

Export Data
Search for Structure

Status:

US Approved Rx (1996)

First approved in 1938

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Sodium channel protein type III alpha subunit

Sodium channel protein type I alpha subunit

Sodium channel protein type VIII alpha subunit

Sodium channel protein type II alpha subunit

Conditions:

Status epilepticus

Phenytoin is an anti-epileptic drug. Phenytoin has been used with much clinical success against all types of epileptiform seizures, except petit mal epilepsy. Phenytoin is a available for oral administration (tablets, capsules, suspension). CEREBYX®...

(fosphenytoin sodium injection) is a prodrug intended for parenteral administration; its active metabolite is phenytoin. CEREBYX should be used only when oral phenytoin administration is not possible. Although several potential targets for phenytoin action have been identified within the CNS (Na-K-ATPase, the GABAA receptor complex, ionotropic glutamate receptors, calcium channels and sigma binding sites) to date, though, the best evidence hinges on the inhibition of voltage-sensitive Na channels in the plasma membrane of neurons undergoing seizure activity.

PHENOBARBITAL

YQE403BP4D

Export Data
Search for Structure

Status:

US Approved Rx (2022)

First marketed in 1912

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

GABA-A receptor; anion channel

Conditions:

Tonic-clonic seizures

Febrile seizures

Hyperbilirubinemia

Status epilepticus

Phenobarbital is a barbiturate derivative used to treat insomnia and anxiety, seizures, hyperbilirubinemia in neonates and cholestasis. Phenobarbital promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride cur...

rents through receptor channels.

PHENOBARBITAL DIETHYLAMINE

RB423CG92E

Export Data
Search for Structure

Status:

US Approved Rx (2022)

First marketed in 1912

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

GABA-A receptor; anion channel

Conditions:

Tonic-clonic seizures

Febrile seizures

Hyperbilirubinemia

Status epilepticus

Phenobarbital is a barbiturate derivative used to treat insomnia and anxiety, seizures, hyperbilirubinemia in neonates and cholestasis. Phenobarbital promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride cur...

rents through receptor channels.

PHENOBARBITAL CALCIUM

1J4G3UJJ69

Export Data
Search for Structure

Status:

US Approved Rx (2022)

First marketed in 1912

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

GABA-A receptor; anion channel

Conditions:

Tonic-clonic seizures

Febrile seizures

Hyperbilirubinemia

Status epilepticus

Phenobarbital is a barbiturate derivative used to treat insomnia and anxiety, seizures, hyperbilirubinemia in neonates and cholestasis. Phenobarbital promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride cur...

rents through receptor channels.

Showing 1 - 10 of 12 results

First page disabled
Previous page disabled
1
Next page
Next page

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1